116 results about "Circulating tumor DNA" patented technology

DNA containing somatic mutations is highly tumor specific and thus, in theory, can provide optimum markers. However, the number of circulating mutant gene fragments is small compared to the number of normal circulating DNA fragments, making it difficult to detect and quantify them with the sensitivity required for meaningful clinical use. We apply a highly sensitive approach to quantify circulating tumor DNA (ctDNA) in body samples of patients. Measurements of ctDNA can be used to reliably monitor tumor dynamics in subjects with cancer, especially those who are undergoing surgery or chemotherapy. This personalized genetic approach can be generally applied.

The invention provides methods and compositions for detecting a mutation in a target gene in a sample of blood or a fraction thereof, including in certain examples, a fraction that includes circulating tumor DNA. The methods can include a tiling PCR reaction, for example a one-sided multiplex tiling reaction. Virtually any type of mutation can be detected with the methods and compositions. In certain embodiments, gene fusions are detected. Improved PCR methods, especially for performing nested multiplex PCR reactions are provided.

Kits and methods providing measurement of tumor burden in a patient derived xenograft (PDX) mouse are described. Exemplary embodiments contemplate taking a sample, typically a blood sample, from a PDX mouse and using a real-time polymerase chain reaction (PCR) system to quantitate both human patient circulating tumor DNA (ctDNA) and mouse DNA. In preferred embodiments, both PCR amplifications are done simultaneously in a multiplex, and a highly polymorphic human DNA target sequence is amplified for high sensitivity, allowing for small volume samples, typically 50-100 μL, of mouse blood. Serial evaluations are possible because the mouse can survive withdrawal of these small volumes of blood. A related method allows for quantitation of ctDNA in the presence of human immune cells added to a “humanized” mouse. These relatively quick and easy methods of determining tumor burden in PDX mice can have predictive value for the efficacy of cancer treatments in human patients.

Disclosed are methods and compositions for enriching nucleic acid fragments from a sample that include one or more target region of interest. In certain aspects, a sample of double stranded nucleic acid fragments having a strand-linking adapter at one end and a non-strand-linking adapter at the other end are denatured and contacted with capture probes specific for a target sequence of interest. Capture probe-bound fragments are isolated from the sample, e.g., using a solid substrate specific for the binding moiety on the capture probes, and are renatured for downstream processing, thus maintaining the original double-stranded region. This enrichment process does not require amplification and as such maintains the nucleic acids in their native states. The disclosed enrichment process and compositions are suitable for analyzing nucleic acids that are fragmented and/or damaged, e.g., cell-free DNA such as circulating tumor DNA, as well as nucleic acids that are many kilobases in length.

The invention provides a biological information processing method for analyzing circulating tumor DNA (deoxyribonucleic acid). The method includes 1), performing cfDNA extraction, database creating and sequencing; 2), performing sequencing-data quality control and sequencing comparison; 3), performing sequencing data correction; 4), using two pieces of software to simultaneously perform gene mutation detection on the sequencing data corrected in the step 3) and summing and integrating analysis results of the software; 5), establishing a mutant trusted data set by the aid of a sequence corrected in the step 3) and using the data set to provide credibility support to a mutation result acquired in the step 4). The ctDNA in the cfDNA is taken as a detection object, detection can be performed by only collecting a small amount of peripheral blood of a subject, and conciseness and convenience in sample collection are achieved.

The invention relates to a device for detecting gene fusion of circulating tumor DNA (deoxyribonucleic acid) samples. The device comprises a sequencing data acquisition module, a comparison module, a re-comparison module, a real fusion breakpoint judgment module and an output module. The device for detecting the gene fusion of the circulating tumor DNA samples has the advantages of high detection speed and stability and low resource requirement.

The invention relates to a device for detecting somatic cell mutation by circulating tumor DNA (deoxyribonucleic acid) samples. The device comprises a data acquisition module, a mutation frequency statistics module, a comparison module, a judgment module and a detection result output module. The device for detecting the somatic cell mutation by the aid of the circulating tumor DNA samples has the advantages that system errors can be accurately differentiated from the real somatic cell mutation by the device, accordingly, the sensitivity can be improved, and false positive and false negative can be reduced.

The invention discloses a circulating tumor DNA EGFR (Epidermal Growth Factor Receptor) detecting technology and a reagent kit thereof. The circulating tumor DNA EGFR detecting technology comprises the following steps: step 1, designing a synthetic primer, a closed probe and a detecting probe for a mutation site; step 2, processing a sample and extracting DNA; step 3, applying the circulating tumor DNA EGFR detecting technology to the reagent kit, and establishing a PCR amplified reaction system. According to the circulating tumor DNA EGFR detecting technology disclosed by the invention, the specific MGB Blocker probe, the EGFR specific probe and the primer are adopted to detect the EGFR mutation in the circulating tumor DNA; the MGB Blocker probe is utilized to retard nonspecific amplification of the EGFR wild type genome and improves the sensitivity; the circulating tumor DNA EGFR detecting technology can be used for detecting the EGFR mutation in the circulating tumor DNA, is simple to operate, cheap in detection, capable of being popularized at a large scale and high in detection speed; the detecting process can be completed for about 2 hours.

The invention discloses a liquid drop capturing chip. The liquid drop capturing chip comprises a plurality of fluid micro channels arranged in parallel, wherein a plurality of liquid drop capturing structures are formed along the fluid micro channels at intervals; the liquid drop capturing structures comprise liquid drop entering ends and inhibition liquid drop flowing-out ends; and the inhibition liquid drop flowing-out ends are communicated with the adjacent fluid micro channels. The invention further discloses a fully integrated digital PCR chip based on a seaweed gel liquid drop and application thereof. The digital PCR chip based on the seaweed gel liquid drop, disclosed by the invention, can finish the full process from the generation of liquid drops to capture of the liquid drops and to the detection of the liquid drops. And moreover, seaweed gels are introduced; after the seaweed gels are solidified, the seaweed gel liquid drops are stable, cannot be fused and cannot affect the PCR amplification efficiency; and the method can be applied to the detection of circulating tumor DNA in the blood and other related biology and medical sciences; and due to the introduction of the seaweed gels, the application can be further expanded to single cell analysis and so on.

The embodiment of the invention discloses a method of detecting circular tumor DNA in free DNA of peripheral blood, a kit and an analytic method of a sequencing result thereof. The method of detecting circular tumor DNA comprises the following steps: S1, filling the tail end of cfDNA, and adding a basic group A into 3' of cfDNA; S2, connecting a joint to the tail end of the cfDNA treated in the S1 to obtain a connecting product, wherein the joint contains a molecular tag sequence and an Index sequence; S3, amplifying the connecting product with universal primers Primer 1.0 and Primer7; S4, capturing and enriching the amplified product obtained in the S3 by means of a probe; and S5, amplifying the enriched product obtained in the S4 by using the Primer 7 and Primer 5 and performing sequencing. The system error induced by PCR and sequencing can be removed effectively, so that the sequencing sensitivity of ctDNA is improved effectively.

The invention discloses a method and device for processing a circulating tumor DNA repetitive sequence. The method comprises the steps that sequencing data and a reference genome sequence of to-be-detected circulating tumor DNA are obtained, wherein the sequencing data is obtained by carrying out high-throughput sequencing on the to-be-detected circulating tumor DNA and comprises a plurality of pairs of double-ended sequences; the sequencing data is compared with the reference genome sequence to obtain a first comparison result, wherein the first comparison result at least comprises genome positions, base sequences and corresponding base quality value sequences of the double-ended sequences; the type of each pair of double-ended sequences is determined on the basis of the first comparisonresult, wherein the types comprise independent sequences and repeated sequences. The method and the device solve the problem that a sequencing data processing method in the prior art is used for sequencing samples to delete or mark repetitive sequences and accordingly the accuracy is low.

The invention discloses a probe for detecting a circulating tumor DNA (Deoxyribonucleic Acid) of a human breast cancer and application of the probe, belonging to the field of diagnosis and prevention of diseases. The invention designs a breast cancer selector which consists of DNA segments in mutation regions of related genes of the breast cancer. The circulating tumor DNA (ctDNA) of a breast cancer patient is subjected to liquid-phase hybridization capture by using the probe designed by the selector; after high-throughput sequencing, specific cancer gene variation of a patient is found, and a tumor load is monitored. Compared with a conventional detection means, the probe and the application thereof disclosed by the invention have the characteristics of no invasiveness, high throughout, good sensitivity and specificity, and the like; the probe and the application thereof can be used for better screening and early-stage diagnosis of the human breast cancer and are applied to individualized treatment of cancer.

Disclosed are methods for treating cancer (e.g., solid tumor cancers, lung cancer, bladder head and neck cancer) with an anti-PD-L1 antibody in a patient identified as being responsive to anti-PD-L1 antibody therapy by detecting a mutation in one or more disclosed circulating tumor DNA (ctDNA) markers. Also disclosed are methods for determining the efficacy of anti-PD-L1 therapeutic antibody treatment in a patient having lung cancer or bladder cancer comprising detecting variant allele frequency in ctDNA in plasma samples and determining the difference of the variant allele frequency in ctDNA between the first and at least second plasma samples, wherein a decrease in the variant allele frequency in the at least second plasma sample relative to the first plasma sample identifies the anti-PD-L1 antibody treatment as effective. The disclosure also provides methods of identifying a subject having a cancer responsive to a therapy comprising an anti-PD-L1 antibody by detecting the expression of a mutation in one or more circulating tumor DNA (ctDNA) markers.

The invention discloses a system and a method for tumor heterogeneity assessment and particularly provides a molecular clone analysis method. On the basis of various types of variation detection results of high-throughput sequencing in circulating tumor DNA, all variations are divided into different molecular clones to realize tumor heterogeneity assessment by molecular clone levels. By adoption of the method, tumor heterogeneity assessment based on ctDNA high-throughput variation detection is realized to effectively assist in making of tumor prognosis and treatment schemes.

The invention discloses a detection kit for TMEM101 gene methylation in human peripheral blood circulating tumor DNA for early screening of endometrial cancer. The detection kit is applied to early screening of endometrial cancer and comprises a methylation specific primer of a TMEM101 gene target site, a hydrolysis probe which is specific to the TMEM101 gene, and a primer of a reference gene and a hydrolysis probe of the reference gene, wherein the target site of the TMEM101 gene is at least one CpG site in an upstream and downstream 2000bp interval of a transcription start site of the TMEM101 gene; the reference gene is one or more of GAPDH and beta-actin; and the kit comprises a PCR pre-amplification reaction system and a PCR amplification reaction system. According to the provided detection kit for TMEM101 gene methylation in human peripheral blood circulating tumor DNA for early screening of endometrial cancer, the technical defects that in the prior art, the process is tedious, the detection time is long, the false positive is high, and the early screening of the endometrial cancer blood cannot be traced are overcome.

The present application provides methods for the detection and diagnosis of cancer. In one aspect, the application provides methods for detecting the presence of cancer in an individual by detecting the methylation state of a region in the promoter of the ZNF154 gene. Methods are provided for detection and diagnosis of cancer from circulating tumor DNA which are minimally invasive and have diagnostic utility across different types and sub-types of cancer. In a further aspect, bioinformatics methods are provided to analyze the methylation state of the ZNF154 promoter and relate the methylation state to the likelihood of cancer in the individual.

The present invention provides a method and a reagent for enrichment of circulating tumor DNA, the method comprising the steps of mixing a water phase and an oil phase and shaking the mixture to prepare an emulsion PCR reaction system, and performing emulsion PCR amplification, wherein the water phase comprises peripheral blood plasma DNA as template DNA, a forward primer and a reverse primer, dNTPs, a PCR buffer and a DNA polymerase, the peripheral blood plasma DNA having adapter sequences connected to both ends thereof, and the forward primer and the reverse primer being complementary to the adapter sequences at the two ends respectively; separating the water phase from the oil phase following the emulsion PCR amplification to obtain a PCR amplification product in the water phase; and capturing circulating tumor DNA in the PCR amplification product in the water phase by using a probe sequence that specifically binds to the circulating tumor DNA. The method of the present invention is capable of performing single-molecule high-fidelity ultramicro parallel amplification and effectively capturing peripheral blood plasma ctDNA to provide adequate amount of ctDNA to be used for subsequent sequencing detection.

The invention discloses a kit for amplifying a Her2 (Human epidermal growth factor receptor-2) gene in human peripheral blood circulating tumor DNA (Deoxyribonucleic Acid). By adopting component setting of the kit and a result reading scheme, a detection process is simple and convenient and the operability is strong. A detection result is reliable and has good specificity; meanwhile, a real-time fluorescence PCR (Polymerase Chain Reaction) technology is used for detecting an amplification level of the Her2 gene in a breast cancer tissue specimen through calculating a deltaCt value; the kit can be used for a plurality of research fields including breast cancer auxiliary diagnosis carried out through detection of ctDNA of the blood, clinical application, prognosis and the like.

The invention provides a detection kit to judge whether solid tumors are suited for immunotherapy. The detection kit includes detection reagents for detecting the indexes: tumor mutation load of peripheral blood circulating tumor DNA, HLA typing, HLA state of loss of heterozygosity, PD-L1 membrane expression positive tumor cell percentage, infiltration level of CD8+ immune cells, infiltration level of FOXP3+ immune cells, mRNA expression score of T-cell inflammation related genes, percentage of CD14+CD16-HLA-DR+ monocytes in peripheral blood mononuclear cells, and micro-satellite instability.The invention also provides, correspondingly, a method to judge whether solid tumors are suited for immunotherapy. The kit and method herein can be used to screen patients with solid tumors so as to provide significantly increased objective response rate and have a promising application prospect in terms of clinical screening of patients with solid tumors suited for immunotherapy.

The invention discloses a detection method for low-frequency mutation of circulating tumor DNA (which is called as ctDNA for short in following). The method comprises the following steps: S1, extracting cfDNA from blood plasma; S2, repairing the tail end of the extracted cfDNA and adding A at the 3' end; S3, performing connector connection on a tail end repaired product, wherein a connector contains a random molecular tag sequence and contains an index sequence for distinguishing different samples; S4, performing PCR amplification on a connector connection product; S5, obtaining a target library through a probe; S6, sequencing through illumina Miseq, illumina Nextseq, illumina Hiseq platforms and analyzing offline data. The method is suitable for probe target capturing sequencing, can reduce an offline data repetition rate, can remove PCR and errors generated in a sequencing process, can improve ctDNA detection flexibility and specificity and can reduce a false positive rate.

The invention discloses a method and device for processing repetitive sequences of circulating tumor deoxyribonucleic acid (DNA). The method comprises the following steps of: obtaining sequencing dataof to-be-detected circulating tumor DNA and a reference genomic sequence, wherein the sequencing data are obtained by carrying out high-throughput sequencing on the to-be-detected circulating tumor DNA and comprise a plurality of pairs of double-ended sequences; comparing the sequencing data with the reference genomic sequence to obtain a first comparing result, wherein the first comparing resultat least comprises genomic positions, base sequences and corresponding base mass value sequences of the double-ended sequences; and obtaining at least one consensus sequence and a base mass value sequence corresponding to each consensus sequence on the basis of the first comparing result. By means of the method disclosed by the invention, the technical problem that the accuracy is low when repeated sequence deleting or labeling is carried out on sample sequencing by adopting a sequencing data processing method in the prior art is solved.